Grail Files For $100M IPO, Plans To Launch Multi-Cancer Early Detection Test In 2021

Grail hopes to launch its Galleri test in 2021 as a laboratory developed test and submit a PMA to the US FDA in 2023.

Cancer cells on scientific background.3d illustration

Liquid biopsy company GRAIL, Inc. filed with the US Securities and Exchange Commission to raise up to $100m in an initial public offering with plans to launch its multi-cancer early detection blood test, Galleri, in 2021 as a laboratory-developed test (LDT), the company announced on 9 September. 

Morgan Stanley, Goldman Sachs & Co. LLC and BofA Securities will act as lead underwriting firms for the proposed offering,...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Financing

More from Business